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Abstract
Objectives: After surgical or endovascular revascularization, some ischemic lesions will not heal, while some others will heal at a
variable period of time from the intervention, indicating a multifactorial interaction between local and systematic “wound healing–
promoting” factors. Our objective was to identify predictors of wound healing following revascularization for chronic limb-
threatening ischemia (CLTI). Methods: A literature review was performed to identify published research concerning clinical,
biochemical, and noninvasive methods as predictors of wound healing time and wound-free period after surgical and endovascular
revascularization for CLTI. Results: Our review indicated that potential predictors included local wound factors, wound depth,
patient’s comorbidities, medications, smoking and alcohol abuse, poor vessel runoff, and direct versus indirect revascularization.
Among the clinical biomarkers, platelet-derived growth factor, transforming growth factor b, basic fibroblast growth factor,
tumor necrosis factor a, interleukin (IL) 1, and IL-6 have been proposed as potential predictors. Furthermore, the potential of
noninvasive microcirculation assessment to predict proper wound healing has been the topic of extensive investigation.
Among the novel methods, transcutaneous measurement of oxygen partial pressure, skin perfusion pressure, oxygen-to-see
method, indocyanine green fluorescence imaging, and multispectral optoacoustic tomography have shown promising results.
Conclusions: The risk factor profile of an ischemic lesion in the lower extremities with a delayed/failed healing response, fol-
lowing a successful revascularization, is not fully clarified. Although many predictors have been assessed so far, further research
needs to be done to identify the optimal clinical and biochemical indices and the noninvasive technique assessing the micro-
circulation that is associated with complete wound healing.
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Introduction
Chronic limb-threatening ischemia (CLTI), also referred as
critical limb ischemia, chronic critical limb ischemia, or
severe limb ischemia, is a proxy of lower extremity arterial
disease (LEAD), and it is characterized by chronic, inade-
quate tissue limb perfusion at rest.1 It is clinically defined
as ischemic rest pain in the foot lasting more than 2 weeks,
nonhealing wound, or gangrene that is attributable to objec-
tively proven arterial occlusive disease.1 The CLTI has been
linked to decreased quality of life and substantial morbidity
and mortality,1 and as a result, surgical or endovascular revas-
cularization is regarded as the standard of care in mobile
independently living patients.2,3
Complete wound healing and relief from ischemic symp-
toms are the main goals after surgical or endovascular revas-
cularization for CLTI. However, it has been reported that a
year following revascularization, only 75% of the ischemic
ulcers are completely healed.4 It has been proposed that a
multifactorial model is probably more appropriate to accom-
modate for the complex interaction between local and systema-
tic “wound healing–promoting” factors.
In this study, we have reviewed the current literature con-
cerning clinical, biochemical, and noninvasive methods as pre-
dictors of wound healing time and wound-free period after
surgical and endovascular revascularization for CLTI.
Wound healing incorporates a complex biological process in
which many parallel and interrelated pathways are activated
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and synchronized in order to induce the optimal wound repair.
Hemostasis, inflammation, cellular proliferation, and remodel-
ing are the 4 known wound healing phases.5 Oxygen plays a
central role in each step of the healing process, and it is also
essential for collagen deposition as it acts as a substrate in the
hydroxylation of proline and lysine residues. The LEAD inter-
rupts this normal process by creating a system of localized
hypoxia that chronically impairs proliferation by decreasing
neoangiogenesis.
Risk Factors for Delaying Wound Healing After Lower
Limb Revascularization
1) Local wound factors affecting healing. The role of nega-
tive pressure wound therapy, antibiotics, and hyperbaric
oxygen therapy.
Despite a successful limb revascularization and restoration
of oxygen delivery to the peripheral tissues, delayed
wound healing time may be affected by local wound factors
(Table 1).6 In a dry environment, cells typically dehydrate and
die. Desiccation is an important local factor for delayed wound
healing, while local hydration with a moisture-retentive dres-
sing substantially improves outcomes. Local infection or
abnormal bacterial presence usually produces purulent drai-
nage or exudate and requires attention. Maceration or local
trauma may increase healing time, while any tissue necrosis,
slough, or eschar should be removed to accelerate healing.6
Removal of these local factors keeps the wound clean and
enhances granulation. However, constant manual washout is
impossible. For that reason, negative pressure wound therapy
(NPWT) has been developed. It involves the application of a
wound dressing attached to a vacuum suction machine, which
applies a carefully controlled negative pressure to the wound
and sucks debris and tissue fluid away from the treated area
into a canister. Promising results have been published in the
literature in the past, indicating that NPWT is efficacious, safe,
and cost-effective in treating diabetic foot ulcers (DFUs).7
However, a recent Cochrane meta-analysis has been more
skeptical, indicating that there is only low-certainty evidence
to suggest that NPWT, when compared to wound dressings,
may increase the proportion of wounds healed and reduce the
time to healing for postoperative foot wounds and ulcers among
diabetic patients.8
Another important factor when trying to eliminate local
wound factors that decrease wound healing rate is the use of
antibiotics. Although very useful, there is no indication for
their use in uninfected foot wound as either infection prophy-
laxis or for accelerating wound healing.9 A detailed advice on
empirical antibiotic therapy that may be used as a framework
for local guideline development to support clinicians in the
management of diabetic foot infection was published by Bar-
well et al.10
Concerning other types that promote wound healing in the
local microenvironment, hyperbaric oxygen therapy (HBOT)
has shown conflicting result. In a recent meta-analysis, the
authors have found that HBOT was associated with a greater
reduction in the ulcer wound area than standard therapy.11
However, clinically oriented practice literature has suggested
that only a moderate level of evidence supports the use of
HBOT, and a shared decision-making should be always
followed.12
Finally, among other local factors, pressure to the wound
area is important and common in patients who have neuropa-
thy. Pressure does not only cause wounds but also prevents
healing after revascularization. Among them, total contact
casts were found to be the most effective devices to achieve
ulcer healing. However, they are not without complications and
their impact on cost, compliance, and quality of life is not well
understood.13
2) Clinical effect of wound depth and area upon healing time
Although vascular surgeons commonly use the Rutherford
classification, no wound depth information is included in this
classification system and thus follow-up on patient’s wound
healing progress after revascularization is mainly clinical and
subjective. Texas classification has been used for decades to
describe the depth of the wound, and a recent study underlined
that deep wounds were associated with a high rate of compli-
cating infection, lower wound healing rate, and a longer time to
wound healing.14 Two years ago, Wound, Ischemia, and foot
Infection (WIfI) classification was introduced and recom-
mended to be used in patients with foot ulcer. The WIfI does
not only grade wound depth but also the severity of ischemia
and infection and thus predicts better the risk of amputation and
need for revascularization.15 Naturally, deeper wounds require
more infection control and advanced wound management com-
pared to more shallow wound ulcers. Not only the depths of the
wound but also the area is important: The higher is the number
Table 1. Risk Factors for Delaying Wound Healing after Lower Limb
Revascularization.
Local wound factors Desiccation
Local infection or abnormal
bacterial presence
Maceration
Wound depth Local trauma
Deeper wound
Patient’s comorbidities Diabetes mellitus
Chronic kidney disease
Obesity
Malnutrition
Medications Nonsteroidal anti-
inflammatory drugs
Steroids
Chemotherapeutic agents
Lifestyle factors Smoking
Alcohol abuse
Poor runoff and indirect
revascularization (nonangiosome
targeted)
Inadequate perfusion
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of affected angiosomes by wound, the longer is the time needed
for wound healing.16
3) Patient’s comorbidities as factors delaying response to
tissue injury in LEAD patients
Diabetes mellitus (DM) is probably the most important risk
factor. Peripheral neuropathy leads to decreased sensation of
the foot, while autonomic neuropathy produces skin trophic
changes.17 These mechanisms usually result in increased risk
of secondary infection, which further impairs the proliferating
phase by impairing fibroblast signaling and resulting in poor
granulation tissue formation. Diabetic foot management, apart
from proper revascularization, includes off-loading casting or
orthotics to equalize plantar pressure and moist dressings and
debridement to restore a balanced environment.18 Furthermore,
in patients with diabetes, the anatomical configuration of the
foot changes leads to pathological distribution of skin compres-
sion, and due to neuropathy, the pain sensation that protects the
skin is impaired, leading to ulcers. This same mechanism
impairs would healing, and the offloading therapy is usually
required to allow the wound to heal. More recent healing tech-
niques have shown promising results, like combination of total
casting with cryopreserved human fibroblast-derived dermal
substitute or HBOT. Notably, in a study investigating risk fac-
tors for DFU over a period of 15 years among 25 220 ft from
5588 patients with T1 DM and 7113 patients with T2 DM, the
authors19 have concluded that male sex, age >60 years, high
hemoglobin A1C (HbA1c), long diabetes duration, history of
cardiovascular disease, macro-albuminuria, decreased visual
acuity, advanced diabetic retinopathy, decreased/absent vibra-
tion sense, presence of patient reported symptoms of neuropa-
thy, and absence of foot pulses were independent risk factors
for the development of first time DFU in T1 DM. In T2 DM, the
independent risk factors were the same except age >60 years, a
history of cardiovascular disease, and long diabetes duration.
Interestingly, glycemic variability—the visit-to-visit variation
in HbA1c—seems to play very important role in the develop-
ment of micro- and macrovascular disease in patients with
diabetes. In a relevant study,20 ulcers in patients with low
HbA1c (<58 mmol/mol) and low variability healed faster than
those in patients with high HbA1c and high variability.
Chronic kidney disease (CKD) has been shown to be inde-
pendently associated with decreased wound healing in Ruther-
ford category 5-6 patients, despite successful revascularization
(hazard ratio [HR]: 0.45, 95% confidence intervals [CI]: 0.25-
0.83, P ¼ .010).21 Chronic kidney disease impairs wound heal-
ing due to its complications such as uremia, anemia, and fluid
overload. Furthermore, CKD impairs the healing after transme-
tatarsal (TMT) amputation and predicts the failure of TMT
amputation (odds ratio [OR]: 2.00, 95% CI: 1.1-3.52).22
Furthermore, hemodialysis seems to be a very important pre-
disposing factor for delayed wound healing. In a study by Das
et al,23 wound healing rates were analyzed retrospectively in
patients who underwent successful below-the-knee percuta-
neous transluminal balloon angioplasty for CLTI with tissue
loss. The authors found that patients with end-stage renal dis-
ease receiving dialysis were 2.6 times more prone to wound
nonhealing.
Obesity is another contributing factor mainly due to avascu-
larity of the surrounding adipose tissue, which decreases the
resistance to infection secondary to oxygen deprivation. This,
in turn, compromises collagen and oxygen-dependent cellular
repair processes. A further decreased mobility and inability to
optimally reposition oneself make wound healing proble-
matic.24 Other potential mechanisms include vascular insuffi-
ciencies, cellular and composition modifications, oxidative
stress, alterations in immune mediators, nutritional deficien-
cies, and plausible alterations and deficiencies in obese
individuals.25
Malnutrition may also result in decreased wound healing.
Decreased collagen production, angiogenesis, and fibroblast
proliferation are the shared pathophysiological features among
the disease states that are influenced by low protein intake.
Low serum albumin has been linked with the development of
pressure ulcers. Moreover, vitamin C deficiency contributes to
fragile granulation tissue, while lack of fatty acids threatens
integrity of cell structure.26 As a result, holistic assessment of
nutrition and nutritional support and replacement therapy may
be necessary after a successful revascularization to promote
wound healing.18
4) Medications that may impact wound proliferation
Nonsteroidal anti-inflammatory drugs show an antiproli-
ferative effect on blood vessels and skin while decreasing the
granulocytic inflammatory reaction, thereby delaying healing
time. Furthermore, the anti-inflammatory and immunosuppres-
sant actions of steroids have found to impede wound contrac-
tion and decrease tensile strength; thus, they negatively affect
wound healing. More specifically, glucocorticoids inhibit local
wound fibroblast proliferation and decrease collagen produc-
tion, while they systematically increase blood glucose and inhi-
bit immune system, which further delays wound maturation.27
Moreover, chemotherapeutic agents, such as adriamycin and
bevacizumab, have been implicated for delayed wound healing
in patients with cancer mainly mediated by delayed inflamma-
tory phase of healing, decreased fibrin deposition, and collagen
synthesis and delayed wound contraction.18
5) Smoking and alcohol abuse as lifestyle factors implicated
in wound healing phases
Smoking is highly prevalent among patients with LEAD. Its
effect is mediated through vasoconstriction, stimulation of
accelerating tissue destruction proteases, and immunosuppres-
sion that leads to increased risk of infection. Additionally, pla-
telet activation and subsequent clot formation increase
fibrinogen, which further leads to connective tissue degrada-
tion, while carbon monoxide negatively affects oxygen deliv-
ery to healing wounds.28 Insulin resistance, hyperglycemia,
low protein intake, and high likelihood of infection, usually
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associated with alcohol abuse, are negative wound healing
prognostic factors after revascularization in these patients.29
6) The use of vessel runoff and direct versus indirect revas-
cularization in predicting wound healing time
As oxygen is the requirement for the successful wound heal-
ing, revascularization should aim to restore as good arterial
circulation as possible in the wound area. A strong association
between change in ankle–brachial index (ABI) and toe–bra-
chial index and outcomes following revascularization has been
shown. In a study by Reed et al,30 change in ABI 0.23 was
independently associated with wound healing and less repeat
revascularization. Although clinically appealing, results of sin-
gle- versus multiple-vessel infrapopliteal intervention have
shown that multiple-vessel intervention did not improve out-
comes.31 The vascular surgeon should always assess the dia-
betic foot first with the possibility for revascularization, before
amputation is considered. Adequate initial arterial tissue perfu-
sion may lead to a less extensive amputation. However, early
recognition and aggressive surgical drainage of foot sepsis fol-
lowed by surgical revascularization is sometimes mandatory.32
Although revascularization represents the primary therapy
for DFU, a more “targeted and localized approach” has been
proposed. According to the angiosome theory, revasculariza-
tion of the angiosome where the wound exists (angiosome-
targeted revascularization) leads to better wound healing and
limb salvage compared to the so-called nontargeted revascular-
ization, where the wound angiosome gets circulation through
collaterals from the artery that has been revascularized. There
are several retrospective studies which have shown that wound
healing is more comprehensive and faster after targeted revas-
cularization than nontargeted revascularization.33 Most of
these studies include only endovascular revascularizations, and
indeed, also some evidence exists that after surgical bypass the
difference in wound healing between targeted and nontargeted
revascularization is smaller.16 According to criticism regarding
the angiosome concept, the presence of collateral vessels
should provide adequate inflow to the entire foot after bypass
to any of the 3 crural arteries, irrespective of the type of
revascularization.34
7) Wound location
Ischemic tissue lesions located in the mid- and hindfoot has
significantly prolonged ulcer healing time after revasculariza-
tion compared to wounds that are located in forefoot or crural
area (HR: 0.4, 95% CI: 0.1-0.9).35 The reason for this is prob-
ably multifactorial. The heel area is often under pressure when
patient is lying in the bed, and decompression may be insuffi-
cient. Furthermore, if neuropathy impairs the feeling of pain,
there is no signal need to change the position. Another factor
may be arterial circulation to the heel area, which is poor in
many patients, and despite good revascularization, the arteries
leading to the wound area in the heel may be occluded.
Risk Stratification Models and Time to Heal Predictors
After Revascularization
Although it is recognized that ulcer healing is a useful proxy of
successful revascularization for CLTI, not all studies report
this. Interestingly, a review2 has found that among 1914 articles
on revascularization, complete ulcer healing was reported only
in 17 (0.9%) studies. In a study assessing 871 critically
ischemic limbs treated with endovascular approach, the authors
found that the rate of freedom from major amputation at 1 year
reached 88%, whereas the wound healing rate was 67%, and the
median time to wound healing was 146 days.34 Their risk stra-
tification model estimated that nonambulatory status, low albu-
min level, Rutherford 6 category, wound infection, indirect
intervention, and poor below-ankle runoff were independent
predictors for delayed wound healing. After infrainguinal
bypass, another study4 demonstrated that complete tissue heal-
ing, including healing of ischemic tissue lesions and surgical
wounds, at 6 and 12 months were 40% and 75%, respectively,
whereas the median time to complete tissue healing was 190
days. Diabetes was the only significant moderator. A similar
study35 evidenced a 74% complete ulcer healing at 12 months
after the bypass. Interestingly, ischemic tissue lesions located
in the mid- and hindfoot had significantly prolonged ulcer heal-
ing time. Concerning decision between open and endovascular
revascularization, both strategies have shown good results.
However, it seems that although contemporary use of endovas-
cular therapies may result in the avoidance of open surgery in
some patients, the injudicious use of catheter-based therapies
may sometimes lead to diminished success for open surgical
revascularization, potentially hampering a long-term benefit.
As a result, vascular surgeons should be equipped with both
open and endovascular skills when attempting to provide opti-
mal vascular care for wound healing.36
Concerning the impact of direct versus indirect revascular-
ization upon healing time, an interesting study37 showed that
median ulcer healing time was significantly lower (56 +
18 days) in the direct group, compared to 112 + 45 days in the
indirect group. These findings were also confirmed by another
study.38 On the contrary, a study39 assessing outcomes after
distal bypass concluded that only the location and the extent
of the ischemic wounds as well as comorbidities may be more
relevant than the angiosome in terms of wound healing. How-
ever, this study did not investigate whether the collateral devel-
opment was sufficient or whether the arterial disease involved
the connecting arteries between angiosomes. In a study on 545
patients with diabetes and ischemic tissue lesion comparing
angiosome-targeted versus nontargeted both surgical and endo-
vascular revascularization, 1-year wound healing was best
(77%) after targeted bypass and worst after nontargeted angio-
plasty (52%). In this study, also collaterals between angiosomes
and their influence were analyzed. And indeed, in patients who
underwent indirect angioplasty, the 1-year wound healing was
significantly better when collaterals between angiosomes
existed.40 The Cox proportional hazards analysis revealed that
angiosome-targeted revascularization, bypass surgery,
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C-reactive protein 10 mg/dL, and the fewer angiosomes
affected improved wound healing. Interestingly, indirect bypass
surgery also achieved better wound healing rates than angio-
plasty independent of the angiosome oriented strategy. What is
more, another study41 proposed that significant predictors of
sufficient wound healing after revascularization included normal
renal function, a palpable postoperative pedal pulse, a patent
posterior tibial artery past the ankle, and the number of patent
tibial arteries after bypass to the ankle. A list of studies reporting
on time to wound healing is presented in Table 2.
The Need for More “Sophisticated” Indices of Assessing
the Wound Healing Process After Revascularization
Biomarkers. Although historical outcomes, such as graft
patency, amputation-free period, target lesion revasculariza-
tion, are still considered reliable indicators of wound healing
process, there is a demanding need for more accurate
predictors. Among them, b-2-microglobulin, cystatin C, high-
sensitivity C-reactive protein, and glucose have been tradition-
ally involved as predictors among LEAD patients (Table 3).
Other biomarkers of vascular remodeling include the trans-
forming growth factors b1 (TGF-b1), the soluble receptor for
advanced glycation end products, and the plasma thrombos-
pondin, while it is under investigation whether the number of
circulating endothelial progenitor cells (EPCs) may be of value
as a reliable biomarker for LEAD.
Although all these indices have been proposed as surrogates
of LEAD severity,49,50 there is currently no consensus on
which of these biomarkers may be used to reliably assess
microcirculation after revascularization.51 For that reason,
many more biomarkers have specifically tested for the purpose
of evaluating the wound healing process in each of the 4 heal-
ing phases.52 In phase I (hemostasis), the platelet-derived
growth factors (PDGF), along with the vascular endothelial
growth factors (EGFs), fibroblast growth factors (FGFs), and
TGFs play an important role and have been tested as proxies of
ongoing wound. In phase II (inflammation), many growth fac-
tors and cytokines, like PDGF, TGF-b, b-FGF, TNF-a, inter-
leukin (IL) 1, and IL-6, which promote the proliferative phase
of healing, may be used as good biomarkers of promoting
wound healing. In phase III (proliferation), the main process
is the proliferation and migration of the epithelial cells, which
starts with the production of the matrix metalloproteinases
(MMPs) with the aid of EGF, keratinocyte growth factors
(KGFs), and TGF-a, while in the last phase of remodeling, the
number of fibroblasts begins to reduce. Interestingly, studies
have demonstrated that IL-1, IL-6, and MMPs, levels above
normal, and an abnormally high MMP–tissue inhibitor of
metalloproteases ratio are often present in nonhealing wounds.
Apart from these, gene expression has been also tested, with
promising results, while there is currently great interest in
designing and applying a benchmark to identify and validate
pathogenic and nonpathogenic biomarkers of wound healing;
among them, serpinB3 has been identified as a healing wound
biomarker in diabetic patients.53
Modern noninvasive methods evaluating the process of wound
healing. The microcirculation as an additional important factor
of wound healing may be also assessed by novel noninvasive
methods. Among them, the transcutaneous measurement of
oxygen partial pressure (TcpO2) is a polarographic method to
measure pO2 at the skin surface. The TcPO2 is measured using
skin surface sensors at 43C to 45C, it is accurate in noncom-
pressible arteries, and it can be used in diabetic and renal
patients, while a TcPO2 level below a cutoff of 20 or 30 mm
Hg is an independent predictor of complications during chronic
wound healing. Another index of microvascular circulation is
the skin perfusion pressure (SPP). Three different types of
techniques are currently used for the measurement of SPP,
namely, radioisotope clearance, photoplethysmography, and
laser Doppler. Among them, laser Doppler is fast, effective,
and easy to operate and is the most widely used method of
measuring SPP.54 In a study by Yamamoto et al, the authors
have found that an increase in SPP of 20 mm Hg after bypass
surgery was associated with better limb prognosis.55
Novel noninvasive techniques include the oxygen-to-see
method, which is an optical measuring technique that combines
white light spectrometry and laser Doppler flowmetry, map-
ping oxygen saturation, relative hemoglobin, and blood flow in
target tissues. More interestingly, indocyanine green fluores-
cence imaging (ICG-FI) enables the visualization of perfusion
of the entire foot and quantifies the washout of ICG in the
peripheral tissues. Using time–intensity curve extracted from
the ICG-FI record, the perfusion can be quantified.56 The ICG-
FI is a promising tool in the assessment of change in foot
perfusion after revascularization as well as quality control of
the procedure.57,58 More studies are needed to assess the value
of ICG-FI in the wound healing. Another novel method of
microcirculation assessment, namely, the multispectral optoa-
coustic tomography, combines optical imaging with conven-
tional ultrasound. The target tissue is illuminated with pulsed
laser light in the near-infrared range, allowing visualization of
even the tiny arterioles of the foot microcirculation up to a
diameter of 100 mm.59 Although these methods seem quite
promising in assessing the outcome after revascularization and
prognose wound healing, more studies are needed before it can
be implemented in the everyday practice.
Conclusions
Wound healing is a continuous process that combines a cascade
of events leading to repair and regeneration of a local tissue
trauma. However, there are many intrinsic and extrinsic factors
that may delay or completely interrupt this procedure. Among
them, local wound factors, wound depth, patient’s comorbid-
ities, medications, lifestyle factors, poor runoff, and indirect
revascularization have been implicated. Further research needs
to be done to identify the optimal biomarker profile that is
associated with the wound healing process. In addition, we
need more reliable noninvasive methods to predict the healing
potential of the wound.
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Table 2. Studies Reporting on Time to Wound Healing After Lower Limb Revascularization.
Study Inclusion Criteria Outcomes—Time to Wound Healing
Okazaki et al (2018)42 233 patients with CLI and tissue loss who underwent
surgical or endovascular revascularization of the
infrainguinal vessels were reviewed retrospectively
The mean wound healing time in the subgroup of limbs
that achieved wound healing (n ¼ 196) was 143.7 days
Spillerova et al (2015)16 744 (252 propensity score matched pairs) patients with
CLI and tissue lesion
Angiosome-targeted revascularization, 1-year wound
healing 67.3%; angiosome nontargeted
revascularization, 1-year wound healing 71.6%
Lejay et al (2014)37 58 consecutive CLI limbs of 54 diabetic patients
presenting with tissue loss who underwent isolated
BTK bypasses for crural occlusive arterial disease
Median ulcer healing time was 56 + 18 days in direct
group (n ¼ 36) and 112 + 45 days in indirect group
(n ¼ 22, P ¼ .01)
Kret et al (2014)43 97 patients who had tibial/pedal bypass for a foot/ankle
wound were identified and operations classified as
direct revascularization (DR) or indirect
revascularization (IR) based on wound location and
bypass target
Complete wound healing (78% vs 46%; P¼ .001) and time
to complete healing (99 vs 195 days; P ¼ .002) were
superior with DR vs IR
Azuma et al (2012)39 28 CLI patients with tissue loss who underwent distal
bypasses were reviewed
The median ulcer healing time was 47 days in nonrenal
patients with Rutherford category (R) 5, 73 days in
renal patients with R5, 115 days in nonrenal patients
with R6, and 237 days in renal patients with R6
Neville et al (2009)44 48 patients with nonhealing lower extremity wounds
requiring tibial bypass
77% of wounds (n ¼ 33) progressed to complete healing
and 23% of wounds (n ¼ 10) failed to heal with
resultant amputation. In the DR group, there was 91%
healing with a 9% amputation rate. In the IR group,
there was 62% healing with a 38% amputation rate
(P ¼ .03). In those wounds that did heal, total time to
healing was not significantly different in DR (162.4
days) versus IR (159.8 days)
Soderstrom et al (2008)4 148 patients with CLI and tissue loss (Fontaine IV) were
followed prospectively for 1 year after infrainguinal
bypass
The median time to complete tissue healing was 190 days
Atar et al (2005)45 38 elderly patients (mean age 83.3 years) with CLI were
treated with percutaneous balloon angioplasty
Healing of the wounds took between 1 and 7 months
(average 4.45+2.16). In 7 patients (4 with ischemic
wounds and 3 with rest pains), their symptoms did not
improve after the percutaneous balloon angioplasty.
Four patients had subsequent leg amputations and 3
needed revascularization surgery within the 1-year
follow-up
Mlekusch et al (2002)46 40 patients with ischemic ulcers (Fontaine stage IV)
undergoing percutaneous transluminal angioplasty
(PTA)
The median healing interval was 5 months (IQR 2 + 7). A
reappearance of ulcers was found in 9 patients (22%)
Brochado et al (2000)47 11 patients with grade III CLI in whom arteriography
showed femoropopliteal occlusive disease and at least
one genicular branch suitable for receiving a bypass
Over a median time of 19 months (range 6-43 months),
one of the patients showed no clinical improvement.
Of the 8 patients who had a patent graft, the Doppler
ankle–brachial systolic pressure index showed no
change in 1 patient, an increase in 6 patients, and was
not measured in 1 patient. The former patient
underwent a below-knee amputation, whereas the
other 7 patients showed complete healing of their skin
ulcers and sites of minor amputation
Treiman et al (2000)41 91 patients were treated for heal wounds that did not
heal for 1 to 12 months (62% of nonhealing wounds, 3
months or longer). Infrainguinal bypass was performed
for 81 patients, 4 had inflow procedures, 3 had
superficial femoral artery percutaneous transluminal
angioplasty, and 3 had primary below-knee amputation
Sixty-six (73%) of the heel ulcers healed, 14 (16%)
remained nonhealed, and 11 patients (11%) eventually
underwent BKA. For the wounds that healed, the
interval from interventional treatment to healing
ranged from 1 to 6 months (mean, 3.2 months)
Nicoloff et al (1998)48 12 patients who underwent initial infrainguinal bypass
surgery for limb salvage
Wound (operative and ischemic) healing required a mean
of 4.2 months (range, 0.4-48 months) and 25 patients
(22%) had not achieved complete wound healing at the
time of last follow-up or death
Abbreviations: BTK, below the knee; CLI, critical limb ischemia; IQR, interquartile range.
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